Avatar Medical receives FDA clearance for 3D imaging platform

Avatar Medical has received U.S. Food and Drug Administration 510(k) clearance for Avatar Medical Vision, a software platform for 3D medical image processing, review, and surgical planning.

The platform converts CT and MR imaging data into interactive, multidimensional 3D representations for clinical use. Avatar Medical said the clearance enables commercialization in the U.S. and supports use across standard operating room displays, glasses-free 3D systems, and virtual reality environments.

Avatar Medical Vision is designed for preoperative surgical planning and intraoperative image display. The company said the system can be used across imaging-intensive specialties including neurosurgery, ear, nose, and throat procedures, orthopedics, oncology, and interventional radiology.

The clearance also establishes compatibility with Barco’s Eonis 3D glasses-free display. That compatibility forms the basis for Eonis Vision, a joint system from Avatar Medical and Barco that allows clinicians and patients to view patient-specific anatomy together during consultations.

Eonis Vision combines Avatar Medical’s FDA-cleared 3D imaging software with Barco’s medical-grade glasses-free 3D display. The companies describe the system as a way to move from flat, monochrome imaging views toward a shared 3D view of anatomy, findings, and procedural plans.

For radiology and procedural teams, the platform sits at the point where imaging interpretation, surgical planning, and patient communication overlap. CT and MRI already provide detailed anatomic data, but that data is often reviewed on 2D screens or reconstructed in separate workstations. Avatar Medical is positioning its platform as a more intuitive way to review and communicate complex anatomy.

“FDA clearance marks a defining milestone for Avatar Medical and for the future of surgical planning,” said Guillaume Chabin, cofounder and CEO of Avatar Medical.

The company was founded in 2020 and says its software creates lifelike 3D avatars from CT and MRI scans without manual segmentation. That workflow claim matters because manual segmentation can be time-consuming and can limit wider clinical use of 3D models in routine practice.

The platform’s potential value will depend on how easily it integrates into existing imaging workflows, how reliably it represents anatomy across clinical use cases, and whether clinicians find it useful enough to change planning or consultation behavior. Its relevance is strongest in specialties where spatial understanding is central to decision-making, including neurosurgery, oncology, orthopedics, and interventional radiology.

The news is also notable because the clearance includes glasses-free 3D compatibility. If adopted, that could make 3D imaging review more accessible in clinical conversations by removing the need for VR headsets or specialized eyewear.

Avatar Medical said the clearance supports U.S. commercialization. Broader clinical impact will depend on hospital adoption, PACS integration, surgeon and radiologist uptake, and evidence showing that 3D review improves planning, communication, efficiency, or outcomes.